Choice and convenience: can Same-Day injections keep HIV at bay?
NCT ID NCT07335289
First seen Jan 13, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This study looks at whether letting people choose where they get their follow-up HIV prevention shots helps them stick with the treatment. About 400 HIV-negative adults in Massachusetts will receive the long-acting injectable drug lenacapavir, starting on the same day they test negative. The goal is to see if offering home, community, or clinic visits improves persistence compared to clinic-only follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS USE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital Sexual Health Clinic
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.